Inicio › Leucemia mielógena aguda › Florida › Miami
Ensayos clínicos de Leucemia mielógena aguda en Miami, FL
24 estudios para Leucemia mielógena aguda buscan participantes en centros de Miami y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Miami Cancer Institute, Miami
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Miami Cancer Institute, Miami
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Miami Cancer Institute, Miami
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Miami Cancer Institute, Miami
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Miami Cancer Institute, Miami
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ReclutandoFase 3
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
ReclutandoFase 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Nicklaus Children's Hospital, Miami
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
ReclutandoFase 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ReclutandoFase 3
- University of Miami, Miami
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
Reclutando
- University of Miami, Miami
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
ReclutandoFase 2/3
- Bioresearch Partners, Miami
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
ReclutandoFase 2
- University of Miami, Miami
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- University of Miami (peds), Miami
- Niklaus Children's Hospital, Miami
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutandoFase 2/3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
ReclutandoFase 2
- University of Miami, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ReclutandoFase 2
- University of Miami, Miami
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
ReclutandoFase 1
- University of Miami Health System, Miami
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- University of Miami, Miami
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
ReclutandoFase 1
- Sylvester Comprehensive Cancer Center, Miami
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
ReclutandoFase 1/2
- University of Miami - Miller School of Medicine, Miami
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
ReclutandoSe aceptan voluntarios sanos
- University of Miami, Miami
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
ReclutandoFase 1
- University of Miami, Miami
Más información sobre Leucemia mielógena aguda en MedlinePlus
Ensayos de Leucemia mielógena aguda en otras ciudades
- Houston, TX85 estudios
- New York City, NY51 estudios
- Boston, MA44 estudios
- Seattle, WA41 estudios
- Baldwin Park, CA40 estudios
- Columbus, OH35 estudios
- Philadelphia, PA34 estudios
- Durham, NC33 estudios
- Atlanta, GA31 estudios
- Tampa, FL29 estudios
- Chicago, IL26 estudios
- Portland, OR25 estudios
Otros estudios en Miami
- Cáncer de seno42 estudios
- Cáncer (todos los tipos)36 estudios
- Cáncer de pulmón de células no pequeñas31 estudios
- Cáncer de próstata27 estudios
- Obesidad27 estudios
- Cáncer metastásico23 estudios
- Sobrepeso23 estudios
- Cáncer de ovario23 estudios
- Colitis ulcerativa21 estudios
- Mieloma múltiple21 estudios
- Enfermedad de Alzheimer20 estudios
- Cáncer de pulmón20 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.